Article
Immunology
Ling Li, Manzhi Zhao, Caoimhe H. Kiernan, Melisa D. Castro Eiro, Marjan van Meurs, Inge Brouwers-Haspels, Merel E. P. Wilmsen, Dwin G. B. Grashof, Harmen J. G. van de Werken, Rudi W. Hendriks, Yvonne M. Mueller, Peter D. Katsikis
Summary: This study demonstrates that ibrutinib directly ameliorates CTL exhaustion by reducing inhibitory receptor expression, enhancing cytokine production, and modulating the transcription factors TOX and TCF1. Additionally, the effect of ibrutinib is independent of BTK expression, suggesting the involvement of other targets.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Dhananjaya Pal, Kendra R. Vann, Shweta Joshi, Namood E. Sahar, Guillermo A. Morales, Dalia El-Gamal, Tatiana G. Kutateladze, Donald L. Durden
Summary: The study developed a first-in-class inhibitor SRX3262 that simultaneously blocks three driver pathways of MCL and overcomes resistance. The inhibitor destabilizes c-MYC, induces apoptosis, providing a new approach to treat MCL.
Article
Oncology
Fuli Fan, Hyeon Joo Yoo, Sophia Stock, Lei Wang, Yibin Liu, Maria-Luisa Schubert, Sanmei Wang, Brigitte Neuber, Angela Hueckelhoven-Krauss, Ulrike Gern, Anita Schmitt, Carsten Mueller-Tidow, Peter Dreger, Michael Schmitt, Leopold Sellner
Summary: The use of ibrutinib has been shown to improve the viability and expansion of CART cells derived from CLL patients, enriching them with less-differentiated naive-like T cell subsets and reducing exhaustion marker expression. Additionally, ibrutinib enhances the cytokine release capacity of CLL patient-derived CART cells, suggesting it can improve the yield and function of these cell products.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Editorial Material
Hematology
Tatjana Stankovic, Marwan Kwok
Summary: The study demonstrates the clinical benefit of ibrutinib for relapsed hairy cell leukemia in a phase 2 clinical trial.
Article
Oncology
Deborah M. Stephens, Ying Huang, Amy S. Ruppert, Janek S. Walker, Casey B. Cempre, Qiang Fu, Sharyn Baker, Boyu Hu, Harsh Shah, Renee Vadeboncoeur, Kerry A. Rogers, Seema Bhat, Samantha M. Jaglowski, Hank Lockman, Rosa Lapalombella, John C. Byrd, Jennifer A. Woyach
Summary: The combination of selinexor and ibrutinib has demonstrated tolerability and durable responses in patients with relapsed/refractory CLL/NHL. Notable responses were seen in patients with CLL with minimal prior therapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Hematology
Steven Le Gouill, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Olivier Casasnovas, Caroline Bodet-Milin, Sylviane Ragot, Celine Bossard, Nathalie Nadal, Charles Herbaux, Benoit Tessoulin, Emmanuelle Tchernonog, Cedric Rossi, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Simon Rule
Summary: The combination of obinutuzumab, ibrutinib, and venetoclax shows promising synergy in treating relapsed mantle cell lymphoma patients, with high complete response rates and MRD clearance rates observed.
Article
Pharmacology & Pharmacy
Ziwen Lu, Zhixin Wang, Zhigang Tu, Hanqing Liu
Summary: The study suggests that the combination of HSP90 inhibitor ganetespib with BTK inhibitor ibrutinib may be an ideal approach for MCL treatment, as it enhances the effects of ibrutinib on MCL cells by promoting cell cycle arrest, inducing cell apoptosis, increasing DNA damage, and inhibiting tumor growth.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Xiao-tuan Zhang, Xiao-bei Hu, Han-lin Wang, Wei-juan Kan, Lei Xu, Zhi-jia Wang, Yu-qi Xiang, Wen-biao Wu, Bo Feng, Jia-nan Li, An-hui Gao, Tian-cheng Dong, Chun-mei Xia, Yu-bo Zhou, Jia Li
Summary: The study investigates the molecular mechanisms of ibrutinib resistance in diffuse large B-cell lymphoma (DLBCL) and proposes targeting the unfolded protein response (UPR) as a potential strategy to overcome resistance. Combination therapy of UPR activator 2-DG with ibrutinib shows synergistic effects in inhibiting cell growth and inducing apoptosis.
ACTA PHARMACOLOGICA SINICA
(2021)
Article
Hematology
Kerry A. Rogers, Leslie A. Andritsos, Lai Wei, Eric M. McLaughlin, Amy S. Ruppert, Mirela Anghelina, James S. Blachly, Timothy Call, Dai Chihara, Anees Dauki, Ling Guo, S. Percy Ivy, Lacey R. James, Daniel Jones, Robert J. Kreitman, Gerard Lozanski, David M. Lucas, Apollinaire Ngankeu, Mitch Phelps, Farhad Ravandi, Charles A. Schiffer, William E. Carson, Jeffrey A. Jones, Michael R. Grever
Summary: Ibrutinib may have potential benefits for patients with hairy cell leukemia, especially heavily pretreated patients, with favorable disease control outcomes.
Article
Hematology
Shayna Sarosiek, Joshua N. N. Gustine, Catherine A. A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. P. Treon, Jorge J. J. Castillo
Summary: Waldenstrom macroglobulinaemia (WM) is a type of blood cancer with a specific mutation known as MYD88(L265P). This mutation activates the Bruton tyrosine kinase (BTK), promoting the growth and survival of malignant cells. Ibrutinib is a BTK inhibitor approved for the treatment of WM. However, the impact of reducing the dosage of ibrutinib has not been extensively studied.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Cell Biology
Haige Ye, Shengjian Huang, Yang Liu, Zhihong Chen, Michael Wang, Vivian Changying Jiang
Summary: This study focuses on identifying the signalling network rewiring that characterizes the ibrutinib resistant phenotype. Dual targeting of the BCL-2 and PI3-kinase signalling pathways shows significant anti-tumour activity by inhibiting compensatory pathways and inducing apoptosis in MCL.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Jia Liu, Zhuojun Liu, Jing Zhang, Xiaofang Chen, Junge Chen, Linlin Sui, Jian Yu
Summary: In this study, the researchers found that Ibrutinib has a stronger cytotoxic effect on endothelial cells compared to Zanubrutinib, while Acalabrutinib has a very weak cytotoxic effect. Ibrutinib was also found to induce endothelial dysfunction through the stimulation of BMP4 expression. The findings suggest the potential use of Ibrutinib in the treatment of angiogenesis-dependent cancers.
Review
Chemistry, Medicinal
Rong Dong, Youyou Yan, Xiaokang Zeng, Nengming Lin, Biqin Tan
Summary: This review discusses the cardiotoxicity induced by ibrutinib and other selective BTK inhibitors, including the incidence, mechanisms, and practical management strategies for this condition.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Review
Oncology
Sining Zhu, Jaeyong Jung, Eton Victor, Johann Arceo, Samantha Gokhale, Ping Xie
Summary: BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for B cell malignancies, showing superior clinical efficacy and safety compared to chemoimmunotherapy. These drugs have versatile immunomodulatory effects beyond B cells, expanding their therapeutic potential in a variety of human diseases. Clinical trials are underway to test their efficacy in different malignancies, allergies, and COVID-19, with promising results in T cell malignancies and autoimmune diseases.
FRONTIERS IN ONCOLOGY
(2021)
Article
Infectious Diseases
Suzanne Maynard, Jose Ros-Soto, Aris Chaidos, Andrew Innes, Krushika Paleja, Eitan Mirvis, Noora Buti, Harriet Sharp, Renuka Palanicawandar, Dragana Milojkovic
Summary: Immune modulation is emerging as an important therapeutic strategy in COVID-19, with Bruton tyrosine kinase inhibitors (BTKi) showing potential to suppress inflammatory pathways. Continuing BTKi therapy in COVID-19 patients may be beneficial, while further evidence is needed to explore the therapeutic impact of BTKis and other immunomodulatory agents on the clinical course of the disease.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)